Form 4: Theravance Biopharma CEO Rick Winningham Reports Share Disposal for Tax Obligations

CEO Rick Winningham of Theravance Biopharma reports disposing of shares to cover tax obligations related to vesting restricted stock units.

Summary

• Rick E Winningham, CEO of Theravance Biopharma, filed a Form 4 detailing changes in beneficial ownership.
• On May 20, 2025, Winningham disposed of 15,364 ordinary shares at a price of $9.45 per share to satisfy tax obligations.
• This disposal was related to the vesting of previously granted restricted stock units and was not an open market transaction.
• Following the transaction, Winningham directly owns 1,762,780 ordinary shares.
• He also indirectly owns 3,900 shares as custodian and 92,567 shares through a trust.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing related to share disposal for tax purposes. It doesn't inherently indicate positive or negative sentiment, but the lack of open market transaction suggests no major concern.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Disposals to cover tax obligations are common and don't necessarily indicate a negative outlook on the company.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine disposal for tax purposes and does not represent a change in the company's fundamentals.

Key Dates

Keywords

Form 4, Theravance Biopharma, Winningham, Share Disposal, Tax Obligations, Restricted Stock Units, Beneficial Ownership